Medium NAPLEX Pain Management Therapeutics Practice Questions

Mastering pain management is a cornerstone of clinical pharmacy, as it requires a delicate balance between effective analgesia and the mitigation of serious adverse effects like respiratory depression and opioid use disorder. This guide provides Medium NAPLEX Pain Management Therapeutics Practice Questions designed to test your knowledge of equianalgesic dosing, adjuvant therapies, and safety monitoring.

Concept Explanation

NAPLEX Pain Management Therapeutics involves the clinical application of pharmacological principles to treat acute and chronic pain while minimizing risks associated with analgesics. Understanding this topic requires a deep knowledge of the World Health Organization (WHO) analgesic ladder, which guides the step-wise use of non-opioids, weak opioids, and strong opioids. For pharmacy students preparing for the NAPLEX Prep, key areas of focus include the mechanism of action of NSAIDs (COX-1 vs. COX-2 inhibition), the conversion between different opioid formulations using equianalgesic tables, and the management of opioid-induced side effects like constipation and pruritus. Effective pain management also incorporates adjuvant medications—such as gabapentinoids for neuropathic pain or TCAs for fibromyalgia—to provide multimodal analgesia and reduce the total opioid burden.

Solved Examples

Review these worked examples to understand how to approach complex calculation and clinical scenario questions on the exam.

1. Opioid Conversion: A patient is currently taking morphine sulfate extended-release 60 mg PO every 12 hours. The physician wants to switch the patient to hydromorphone PO. Using a conversion ratio of 30 mg oral morphine to 7.5 mg oral hydromorphone, calculate the new daily dose of hydromorphone.
   1. Calculate total daily dose (TDD) of morphine: $$60 \text{ mg} \times 2 = 120 \text{ mg/day}$$
   2. Set up the ratio: $$\frac{30 \text{ mg Morphine}}{7.5 \text{ mg Hydromorphone}} = \frac{120 \text{ mg Morphine}}{x \text{ mg Hydromorphone}}$$
   3. Solve for $x$: $$x = \frac{120 \times 7.5}{30} = 30 \text{ mg Hydromorphone per day}$$
2. Fentanyl Patch Safety: A patient is prescribed a Duragesic (fentanyl) 25 mcg/hr patch. What is the most important counseling point regarding heat exposure?
   1. Explain the mechanism: Heat increases peripheral vasodilation and skin permeability.
   2. Identify the risk: Increased absorption can lead to fatal respiratory depression.
   3. Actionable advice: Avoid heating pads, electric blankets, or saunas over the patch site.
3. NSAID Contraindications: A 68-year-old male with a history of a myocardial infarction 6 months ago and a current CrCl of 25 mL/min requests an OTC recommendation for knee pain. Why is ibuprofen contraindicated?
   1. Cardiovascular risk: NSAIDs (except aspirin) increase the risk of thrombotic events and are avoided post-MI.
   2. Renal risk: NSAIDs inhibit prostaglandins that maintain renal perfusion; with a CrCl < 30 mL/min, they can cause acute kidney injury.
   3. Recommendation: Suggest topical agents or acetaminophen if appropriate.

Practice Questions

1. A patient with chronic cancer pain is taking OxyContin 40 mg PO Q12H. They are experiencing breakthrough pain 3 times a day. What is the appropriate dose of oxycodone IR for breakthrough pain, typically calculated as 10-15% of the total daily opioid dose?
2. Which of the following antidepressants is specifically FDA-approved for the management of fibromyalgia and neuropathic pain associated with diabetic peripheral neuropathy?
3. A patient is being switched from IV morphine to PO morphine. If the patient received 20 mg of IV morphine over the last 24 hours, what is the equivalent PO morphine dose using a 1:3 IV to PO ratio?

4. A patient presents with symptoms of opioid-induced constipation (OIC) that has not responded to lifestyle changes or stimulant laxatives. Which peripherally acting mu-opioid receptor antagonist (PAMORA) is available as an oral tablet for this condition?
5. A patient is prescribed Celebrex (celecoxib). Which allergy in the patient's profile would serve as a contraindication for this specific medication?
6. Calculate the Morphine Milligram Equivalents (MME) for a patient taking hydrocodone/acetaminophen 10/325 mg, one tablet every 6 hours. (Conversion factor for hydrocodone is 1.0).
7. Which opioid is known to cause a significant risk of QT prolongation and requires baseline and periodic EKG monitoring?
8. A patient is using a Lidoderm patch for post-herpetic neuralgia. What is the maximum number of patches that can be applied at one time, and what is the required "off" period?
9. Which medication used for neuropathic pain is a Schedule V controlled substance?
10. A patient has been taking high-dose prednisone for an inflammatory condition for 3 weeks. Why should this medication be tapered rather than stopped abruptly?

For more focused study on specific systems, you may want to review Medium NAPLEX GI Pharmacology Practice Questions or NAPLEX Psychiatric Therapeutics Practice Questions with Answers to see how pain management overlaps with other therapeutic areas.

Answers & Explanations

1. Answer: 10 mg to 15 mg oxycodone IR. The total daily dose (TDD) of oxycodone is $$40 \text{ mg} \times 2 = 80 \text{ mg}$$. Breakthrough doses are usually 10-15% of the TDD. $$80 \times 0.10 = 8 \text{ mg}$$ and $$80 \times 0.15 = 12 \text{ mg}$$. Clinical judgment usually rounds these to common strengths like 5 mg, 10 mg, or 15 mg.
2. Answer: Duloxetine (Cymbalta). Duloxetine is an SNRI with multiple FDA indications, including MDD, GAD, fibromyalgia, and chronic musculoskeletal pain.
3. Answer: 60 mg PO Morphine. Using the 1:3 ratio: $$20 \text{ mg IV} \times 3 = 60 \text{ mg PO}$$.
4. Answer: Naloxegol (Movantik) or Methylnaltrexone (Relistor) tablets. These PAMORAs work by blocking mu-receptors in the gut without crossing the blood-brain barrier, thus not affecting analgesia.
5. Answer: Sulfonamide (Sulfa) allergy. Celecoxib contains a sulfonamide moiety and is contraindicated in patients with documented sulfa allergies.
6. Answer: 40 MME. The patient takes 4 tablets a day (Q6H). $$10 \text{ mg} \times 4 = 40 \text{ mg hydrocodone}$$. Since the conversion factor is 1, the MME is 40.
7. Answer: Methadone. Methadone has a long and variable half-life and is associated with QTc prolongation and Torsades de Pointes.
8. Answer: Up to 3 patches for 12 hours on and 12 hours off. Overexposure to lidocaine can lead to systemic toxicity, including arrhythmias and seizures.
9. Answer: Pregabalin (Lyrica). Unlike gabapentin (which is non-controlled in most states), pregabalin is a Schedule V substance due to its potential for mild euphoria.
10. Answer: To prevent adrenal insufficiency. Prolonged corticosteroid use suppresses the Hypothalamic-Pituitary-Adrenal (HPA) axis; tapering allows the adrenal glands to resume natural cortisol production. Use the AI Flashcard Generator to memorize these tapering schedules.

1. Which of the following is the mechanism of action for Sumatriptan?

• AMu-opioid receptor agonist
• B5-HT1B/1D receptor agonist
• CNMDA receptor antagonist
• DCOX-2 selective inhibitor

Frequently Asked Questions

What is the difference between opioid potency and efficacy?

Potency refers to the amount of drug required to produce a specific effect, whereas efficacy is the maximum effect a drug can produce. In pain management, a highly potent drug like fentanyl requires a smaller dose than morphine to achieve the same level of pain relief.

How do you calculate a breakthrough pain dose for opioids?

Breakthrough doses are typically calculated as 10% to 15% of the total 24-hour scheduled opioid dose. These doses are usually administered as immediate-release formulations every 4 to 6 hours as needed.

Why is meperidine rarely used for chronic pain?

Meperidine is avoided for chronic use because its metabolite, normeperidine, is renally cleared and can accumulate, leading to CNS toxicity and seizures. It is generally limited to short-term use or specific cases like post-operative shivering.

What are the signs of salicylate toxicity?

Early signs of salicylate (aspirin) toxicity include tinnitus (ringing in the ears), nausea, and vomiting. Severe toxicity can progress to metabolic acidosis, respiratory alkalosis, and altered mental status.

When should a provider consider using an adjuvant for pain?

Adjuvants should be considered when the pain has a neuropathic component or when a patient is experiencing inadequate relief or dose-limiting side effects from primary analgesics. Common adjuvants include antidepressants, anticonvulsants, and topical anesthetics.

What is the "incomplete cross-tolerance" rule in opioid rotation?

When switching a patient from one opioid to another, the calculated equianalgesic dose is often reduced by 25% to 50%. This accounts for the fact that the patient may not be fully tolerant to the new opioid, reducing the risk of accidental overdose.